Thomson Reuters today announced that it has suspended the divestiture process for its healthcare business. The company had revealed plans to sell the division in June.
“Since announcing the planned divestiture, global economic conditions have become more challenging and the company believes they are not conducive to concluding a transaction that reflects the fair value of the healthcare business at this time,” the company stated in a press release announcing the suspension.
“Thomson Reuters is committed to continuing to invest in and grow the healthcare business until improved market conditions allow the company to complete a divestiture at attractive terms,” the statement continued.
In 2010, the healthcare division had revenues of approximately $450 million and an annual operating margin comparable to the company’s consolidated margin of 19.3 percent.